Cushing's Disease Clinical Trial
Official title:
Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease
This study aims at investigating the complications of Cushing's disease in "de novo" patients. A series of investigations will assay before treatment and every year thereafter during a 3 years follow-up period the various complications of the disease. These investigations will determine the presence and severity of cardiovascular, metabolic, and bone complications as well as the Quality of Life. Outcome of these complications after treatment, especially after pituitary surgery will be monitored, as well as cortisol levels.
At inclusion the following will be investigated and recorded :
- demographic and personal medical history.
- Familial medical history related to osteoporosis, cardiovascular disorders and
thromboembolism.
- Current medical treatment.
- Physical examination.
- Assessment of basal 24hrs urinary cortisol and salivary cortisol.
- At baseline (i.e. before specific treatment of Cortisol excess):
- physical examination,
- routine biology,
- HbA1C, fasting glucose and oral glucose load,
- cholesterol, triglyceride, HDL & LDL,
- coagulation and fibrinolysis investigation,
- 24hrs urinary cortisol and salivary cortisol, urinary labstick test.
- EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US,
- ophthalmology examination,
- spine X-Ray, bone densitometry,
- QoL questionnaires (SF-36, QoLCushing, Beck BDI-II).
Every year during a 3 years follow-up the following will be investigated :
- Current medical treatment.
- Physical examination.
- Assessment of basal routine biology,
- HbA1C, fasting glucose,
- cholesterol, triglyceride, HDL & LDL,
- coagulation and fibrinolysis investigation,
- 24hrs urinary cortisol and salivary cortisol, urinary labstick test.
- EKG, cardiac ultrasound, cardiac CT-scan (if abnormal initially), arterial and venous
US,
- ophthalmology examination, bone densitometry,
- QoL questionnaires (SF-36, QoLCushing, Beck BDI-II).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00881283 -
Long-term Cardiovascular Risk in Cured Cushing's Patients
|
||
Completed |
NCT02697734 -
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
|
Phase 3 | |
Completed |
NCT01374906 -
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
|
Phase 3 | |
Recruiting |
NCT03364803 -
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
|
||
Not yet recruiting |
NCT02603653 -
Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease
|
N/A | |
Completed |
NCT01371565 -
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
|
Phase 3 | |
Recruiting |
NCT00845351 -
Preoperative Bexarotene Treatment for Cushing's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00889525 -
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
|
Phase 3 | |
Completed |
NCT02060383 -
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
|
Phase 4 | |
Recruiting |
NCT03474601 -
Seoul National University Pituitary Disease Cohort Study
|
||
Recruiting |
NCT04339751 -
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease
|
Phase 2 | |
Not yet recruiting |
NCT04569591 -
Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease
|
N/A | |
Recruiting |
NCT02484755 -
Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease
|
Phase 2 | |
Completed |
NCT01794793 -
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
|
Phase 4 | |
Completed |
NCT00434148 -
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
|
Phase 3 | |
Completed |
NCT03346954 -
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease
|
N/A | |
Withdrawn |
NCT01925092 -
Mifepristone in Children With Refractory Cushing's Disease
|
Phase 3 | |
Completed |
NCT01582061 -
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
|
Phase 3 | |
Recruiting |
NCT03708900 -
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease
|
Phase 2 | |
Terminated |
NCT00612066 -
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
|
Phase 2 |